[Clinical research of targeting therapy for cancer stem cells]

Area of Science:

• Oncology
• Cancer Biology
• Drug Development

Context:

• Cancer stem cells (CSCs) contribute to treatment resistance and disease progression in various malignancies.
• Identifying and targeting CSCs is crucial for achieving a definitive cure.
• Current treatments often fail to eradicate CSCs, necessitating novel therapeutic strategies.

Purpose:

• To evaluate the safety and confirm the mechanism of action of a specific inhibitor targeting the xCT transporter on CD44 splice variant (CD44v) expressing cancer stem-like cells.
• To assess the potential of targeting cancer stem cells as a therapeutic approach.

Summary:

• A phase I clinical study was conducted to investigate a specific inhibitor of xCT, a glutamate-cystine transporter crucial for cancer stem cell survival.
• This inhibitor targets CD44 splice variant (CD44v) expressing cancer stem-like cells, which are implicated in treatment resistance and tumor recurrence.
• The study aimed to confirm the drug's mode of action in patients.

Impact:

• This research contributes to the development of novel cancer therapies aimed at eradicating cancer stem cells.
• Findings may pave the way for more effective combination treatments, potentially improving cure rates for difficult-to-treat malignancies.
• Ongoing clinical studies will further elucidate the efficacy of this targeted approach in combination with standard chemotherapy.